Navigation Links
Randomize Gene Sequences with New PCR Mutagenesis Kit



GeneMorph PCR mutagenesis kit produces a unique mutational spectrum

Janice Cline Holly Hogrefe

Stratagene

The GeneMorph PCR mutagenesis kit simplifies the process of constructing mutant libraries for protein evolution and structure-function studies. Errors are introduced during PCR at low, moderate, or high mutation frequencies using a single set of optimal reaction conditions. The kit features Mutazyme DNA polymerase, a novel error-prone DNA polymerase mutant developed at Stratagene. Mutazyme DNA polymerase produces all possible transition and transversion mutations with minimal bias, and its mutational spectrum is distinct from that of Taq DNA polymerase. Unlike current Taq- based protocols, the GeneMorph method is robust and can be applied to mutagenesis of long targets (1-10 kb).

Error-prone PCR is a random mutagenesis technique for introducing amino acid changes into proteins. Mutations are deliberately introduced during PCR through the use of error-prone DNA polymerases and reaction conditions.1,2 Randomized DNA sequences are cloned into expression vectors, and the resulting mutant libraries are screened for altered or improved protein activity. To analyze structure-function relationships, mutation frequencies of one amino acid change (1-2 nucleotide changes) per gene are desired, while directed evolution studies typically empl
'"/>

Source:


Page: All 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. New Yeast Cloning System for Producing Proteins with Native Amino Acid Sequences
2. Selecting siRNA Sequences to Incorporate into the pSilencer Vectors
3. Big Blue Rodent Cell Cultures for Mutagenesis Studies
4. High-Efficiency Site-Directed Mutagenesis of Large Plasmid Vectors

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Randomize Gene Sequences with New PCR Mutagenesis Kit

(Date:11/6/2009)...Nov. 6 ,, 3Q09 Cor...Qutenza(TM) E.U. Marketing Authorization to Astell...in commercial readiness activities Expanded manag...arketing; and Director, Commercial Operations App...d Audit Committee chairman , Upcoming 2009 ...
(Date:11/6/2009)... The agenda for Arrowhead’s 2010 Personalize...o take place on February 22-24, 2010 in Philadelph...ce we will highlight key issues in forming partner...experiences. , Minneapoli...rrowhead’s 2010 Personalized Medicine Partn...
(Date:11/5/2009)...ov. 5 DSM Pharmaceutical Products ...lliance with Galenix, Saint Jean D,Illac, France, ...anufacturing partner for Galenix commercial produc...ollaborate on business development opportunities c...sed on the strength of Galenix in drug product dev...
(Date:11/5/2009)... Transgenomic, Inc. (OTC...esults for the quarter ended September 30, 2009. T...e tables that follow. ,, Third Quarter 2009 ,...r $0.01 per share for the third quarter of 2009 as...hare for the third quarter of 2008. ,, Net sal...
Breaking Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7
...on (Nasdaq: DNDN ) announced today the closing o...ring of 10,700,000 shares of its common stock, whi...19.20 per share. On May 8, 2009, Deutsche Bank Se...ing, exercised in full its over-allotment option t...n stock at the public offering price of $19.20 per...
...A has approved an,Investigational New Drug (IND) a... phase I clinical study with its selective PLK-1 s...r. PLK-1 is a mitotic kinase required for,the prol...ally bioavailable,highly efficient and well tolera... dosing. This unique inhibitor adds another promis...
...nc. (Xennex) announced today a major leap for Gene...ilable at http://www.genecards.org/v3 . , , ...ntly upgraded infrastructure, including a comprehe... sophisticated and speedier search engine. It prov...rgeted queries, a user-friendly display and clear ...
Other Biology Technology:Dendreon Announces Closing of Common Stock Offering 2Dendreon Announces Closing of Common Stock Offering 3Nerviano Medical Sciences Receives Approval From the FDA to Enter Phase I Clinical Trials for Their Polo Like Kinase (PLK) Inhibitor 2GeneCards(R) Version 3.0 Beta Released 2GeneCards(R) Version 3.0 Beta Released 3
(Date:11/4/2009)... 20 Quest Diagnostics In...ider of diagnostic testing, information and servic...tember 30, 2009, income from continuing operations... from $160 million, or $0.81 per diluted share, fo...r results were reduced by a $0.03 per share charge...
(Date:11/4/2009).... 20 Aware, Inc. (Nasdaq...ogy and biometrics software, today reported financ... 30, 2009. ,, Michael Tzannes, Aware,s Chairm...ay, we announced an agreement to sell our DSL and ...less semiconductor company being spun out of Infin...
(Date:11/4/2009)...ct. 23 GenVault Corporation, the l...for genomic discovery, medicine and identification...lt,s President and CEO, will be presenting at the ... 26th and 27th in La Jolla, CA. ,, During the p...f the company together with recent customer, techn...
Breaking Biology News(10 mins):Quest Diagnostics Reports Strong Performance in Third Quarter 2009 2Quest Diagnostics Reports Strong Performance in Third Quarter 2009 3Quest Diagnostics Reports Strong Performance in Third Quarter 2009 4Quest Diagnostics Reports Strong Performance in Third Quarter 2009 5Quest Diagnostics Reports Strong Performance in Third Quarter 2009 6Quest Diagnostics Reports Strong Performance in Third Quarter 2009 7Quest Diagnostics Reports Strong Performance in Third Quarter 2009 8Quest Diagnostics Reports Strong Performance in Third Quarter 2009 9Quest Diagnostics Reports Strong Performance in Third Quarter 2009 10Quest Diagnostics Reports Strong Performance in Third Quarter 2009 11Quest Diagnostics Reports Strong Performance in Third Quarter 2009 12Quest Diagnostics Reports Strong Performance in Third Quarter 2009 13Quest Diagnostics Reports Strong Performance in Third Quarter 2009 14Quest Diagnostics Reports Strong Performance in Third Quarter 2009 15Quest Diagnostics Reports Strong Performance in Third Quarter 2009 16Quest Diagnostics Reports Strong Performance in Third Quarter 2009 17Aware, Inc. Reports Third Quarter 2009 Financial Results 2Aware, Inc. Reports Third Quarter 2009 Financial Results 3Aware, Inc. Reports Third Quarter 2009 Financial Results 4Aware, Inc. Reports Third Quarter 2009 Financial Results 5Aware, Inc. Reports Third Quarter 2009 Financial Results 6Aware, Inc. Reports Third Quarter 2009 Financial Results 7GenVault Corporation to Present at the 2009 BIOCOM Investor Conference 2Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes 5004 1Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes 5004 2Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes 5004 3Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes 5004 4GENova gains access to Big Pharma 57148 1GENova gains access to Big Pharma 57148 2GENova gains access to Big Pharma 57148 3Frost 26 Sullivan 3A First Responders Communication Interoperability A Vital Need for Life Saving Services 57146 1Frost 26 Sullivan 3A First Responders Communication Interoperability A Vital Need for Life Saving Services 57146 2
...f the words "parasitic worms," it,s a fact that so...At Michigan State University, researcher Linda Man...vestigating the role that parasites can play in tr...ns. , Her research is part of a more than $10 mil...g the Food and Waterborne Diseases Integrated Rese...
...enomes (IMG) data management system of the U.S. De...) has been released to the public. IMG 1.5 now con...chaeal, 15 eukaryotic genomes and 259 bacterial ph...genomes. , IMG 1.5 contains 62 finished and 100 ...total to 162 microbial genomes generated in-house....
...eloped a new low-cost system that analyzes scatter...plications in medicine, food processing and homela...technologies. , The technique - Bacteria Rapid De...s by shining a laser through a petri dish containi.... , "Unlike conventional methods, we don,t have ...
Other Biology News:Parasitic worms used to fight bowel disease 2DOE JGI releases IMG 1.5 with curated archaeal genomes 2Purdue creates new low-cost system to detect bacteria 2Purdue creates new low-cost system to detect bacteria 3Purdue creates new low-cost system to detect bacteria 4
MUTAN SUPER EXPRESS KM 20 RXN from Takara Mirus Bio
...omics Analyzer Mass Standards Kit includes reagent...timize instrument parameters, and calibrate the ma...s designed for use with the 4700 Proteomics Analyz...dards in the kit require minimal preparation and w...
Adaptor BamH I-Sma I from Takara Mirus Bio
Adaptor EcoR I Sma I from Takara Mirus Bio
Biology Products: